Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma After Axicabtagene Ciloleucel
H. Lee Moffitt Cancer Center and Research Institute
Summary
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients must have histologically documented history of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. * Adult males or females must be of age ≥18 years or older at time of signing informed consent. * Patients must be capable of understanding the protocol with willingness to comply with all study procedures including availability for the duration of the study. * Patients must be able to understand and willing…
Interventions
- DrugTafasitamab
The recommended dose of tafasitamab is 12 mg/kg.
- DrugLenalidomide
The starting dose for lenalidomide will be 25 mg PO daily.
Location
- Moffitt Cancer CenterTampa, Florida